Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 235,024
  • Shares Outstanding, K 100,010
  • Annual Sales, $ 30,480 K
  • Annual Income, $ -96,970 K
  • 60-Month Beta 2.05
  • Price/Sales 7.22
  • Price/Cash Flow N/A
  • Price/Book 6.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.24
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +32.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.09 +9.09%
on 10/31/19
2.85 -20.00%
on 11/05/19
+0.03 (+1.33%)
since 10/18/19
3-Month
1.91 +19.06%
on 10/02/19
2.85 -20.00%
on 11/05/19
-0.09 (-3.80%)
since 08/16/19
52-Week
1.91 +19.06%
on 10/02/19
5.47 -58.32%
on 12/03/18
-2.84 (-55.47%)
since 11/16/18

Most Recent Stories

More News
Inovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November...

INO : 2.28 (-2.98%)
Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

AZN : 47.94 (+1.05%)
SNY : 46.71 (+1.30%)
REGN : 340.19 (-1.36%)
INO : 2.28 (-2.98%)
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of 0.00% and -68.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

INO : 2.28 (-2.98%)
Inovio: 3Q Earnings Snapshot

PLYMOUTH MEETING, Pa. (AP) _ Inovio Pharmaceuticals Inc. (INO) on Tuesday reported a loss of $23.1 million in its third quarter.

INO : 2.28 (-2.98%)
Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious...

INO : 2.28 (-2.98%)
Merck's Ebola Vaccine Gets Conditional Approval in Europe

European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

MRK : 84.13 (-0.91%)
GSK : 44.33 (+0.54%)
REGN : 340.19 (-1.36%)
INO : 2.28 (-2.98%)
Patients Turn to Advanced Technology in Order to Combat Cancer

Over the past two decades, cancer-related deaths in the U.S. have declined significantly. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American...

ONPH : 0.0299 (-0.33%)
INO : 2.28 (-2.98%)
REGN : 340.19 (-1.36%)
AVEO : 0.66 (+4.40%)
SLS : 4.20 (-18.45%)
NWBO : 0.2200 (-0.99%)
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INO : 2.28 (-2.98%)
Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months

INO : 2.28 (-2.98%)
REGN : 340.19 (-1.36%)
Inovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that third quarter 2019 financial results will be released after the market close on November 12, 2019. Following the release, the Company will...

INO : 2.28 (-2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade INO with:

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

2nd Resistance Point 2.43
1st Resistance Point 2.36
Last Price 2.28
1st Support Level 2.23
2nd Support Level 2.17

See More

52-Week High 5.47
Fibonacci 61.8% 4.11
Fibonacci 50% 3.69
Fibonacci 38.2% 3.27
Last Price 2.28
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar